Detection and Characterization of the Heterozygote State for Lipoprotein Lipase Deficiency

Stephan P. Babirak, Per-Henrik Iverius, Wilfred Y. Fujimoto, and John D. Brunzell

Because there are no characteristic clinical or biochemical manifestations, the heterozygote state for lipoprotein lipase (LPL) deficiency has been difficult to detect. Measurements of postheparin plasma LPL activity and of LPL mass were performed in six families of probands with LPL deficiency to characterize the heterozygote state. LPL mass was measured in a sandwich enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody (5D2) that had been produced against bovine milk LPL. Thirteen obligate heterozygotes from these families had reduced LPL activity and mass below the 95th percent confidence limits of 34 normal controls, while one obligate heterozygote had LPL activity and mass between the 90th and 95th percent confidence limits. Potential heterozygotes in these families were identified as normal (n=8) or heterozygotes (n=6) by comparison to the 95th percent confidence limits in the controls. Some relatives in four of the six families exhibited mild hyperlipidemia, similar to the pattern seen in familial combined hyperlipidemia (FCHL). The hyperlipidemia segregated with the heterozygote state for LPL deficiency in these families (p<0.03). High density lipoprotein (HDL) cholesterol was significantly reduced in the heterozygotes for LPL deficiency (p<0.01). The measurement of LPL activity and mass allows identification of the heterozygote state for LPL deficiency, which is characterized by variable expressions of hyperlipidemia and reduced HDL cholesterol. These results suggest that the heterozygote state for LPL deficiency may form one subset of FCHL. (Atherosclerosis 9:325–334, May/June 1989)

Lipoprotein lipase (LPL) deficiency is a rare clinical disorder with a frequency estimated to be less than one in a million. 1,2,3 These patients have absent or very low LPL activity measurable in plasma after heparin. 4 Adipose tissue LPL activity is also very low or undetectable in these patients. 4,5 Classical LPL deficiency is detected in early childhood; patients show failure to thrive, colicky abdominal pain, pancreatitis, eruptive xanthomata, lacteal plasma, and other signs or symptoms of the chylomicronemia syndrome. Partial LPL deficiency syndromes have also been reported and may even be less prevalent. 1,4 In patients with classical LPL deficiency, the grossly lipemic plasma results from a decreased clearance of triglyceride-rich lipoproteins. 5,6 In addition, there is a marked reduction in high density lipoprotein (HDL) and low density lipoprotein (LDL), with mildly to moderately increased very low density lipoprotein (VLDL). These patients have normal to elevated apolipoprotein (apo) C-II levels.

Familial LPL deficiency is believed to have an autosomal recessive mode of inheritance, and consanguinity is common. The heterozygote state has been difficult to detect because postheparin enzyme activity can be low, or it may be normal. 5,7,8,10-13 Measurement of adipose tissue LPL activity has also not been reliable for the identification of the heterozygote state. 5,8 Multiple lipoprotein phenotypes have been noted in the relatives of some probands with LPL deficiency. 1,7,9,10,12-16 Similar to the pattern seen in familial combined hyperlipidemia (FCHL). 16 That is, hypertriglyceridemia (phenotype IV), hypercholesterolemia (phenotype IIA), or both (phenotype IIB) have been observed in successive generations. It is not known if the hyperlipidemia in the families of LPL-deficient probands is associated with the heterozygote state for LPL deficiency. 5,8

The purpose of this investigation was to study LPL-deficient patients and their respective families in order to characterize the heterozygote state. When measuring LPL activity and LPL mass by enzyme-linked immunosorbent assay (ELISA), the heterozygote state for LPL deficiency in six families was characterized by reduced levels of LPL activity and mass. Relatives in four of six families with LPL-deficient patient(s) exhibited mild hyperlipidemia similar to FCHL. The hyperlipidemia segregated with the heterozygote state for LPL deficiency and was associated with reduced HDL cholesterol. Some adult heterozygotes had elevated apo B levels, which is an observation also seen in patients with FCHL. This study identifies and characterizes a genetic disorder, the heterozygote state for LPL deficiency, which may be one subset of FCHL.
Figure 1. Pedigrees from the families of eight lipoprotein lipase (LPL)-deficient patients (C). Included are the lipid phenotypes: normolipemic (C), hypertriglyceridemic (C), hypercholesterolemic and hypertriglyceridemic (a), and variable lipid phenotypes (C) as reported in Table 2. Single (C) or multiple (a) relatives were not studied. The heavy line (C–C) indicates consanguinity. Subject II-1 in Family 2106 had normal LPL activity and mass.

Methods

Materials

Aminopterin, hypoxanthine, thymidine 2-mercaptoethanol, caprylic acid, α-phenylenediamine dihydrochloride, 2,6,10,14-tetramethylpentadecane (Pristane), Tween 20, heparin (porcine intestinal mucosa, 140 USP units/mg), bovine serum albumin, and horseradish peroxidase (type VI) were obtained from Sigma Chemical Company, St. Louis, Missouri. Polyethylene glycol 4000 (PEG 4000) was from E. Merck, Darmstadt, West Germany; lecithin was from Serdy Research Lab, London, Ontario; tri-1-14C-colate was from Amersham, Arlington Heights, Illinois; and ammonium sulfate and glycerol were from J.T. Baker Chemical Company, Phillipsburg, New Jersey. Goat antisera to mouse immunoglobulins and horseradish peroxidase conjugates of rabbit antibodies to goat immunoglobulins and of goat antibodies to mouse immunoglobulins were obtained from American Qualex International, Incorporated, La Mirada, California. Microtiter plates (96 wells, Nunc Immunoplate I with certificate) were purchased from Scientific Resource Associates, Bellevue, Washington. Dulbecco's modified Eagle medium (DMEM); glutamine, and sodium pyruvate were from GibCo Laboratories, Grand Island, New York; fetal bovine serum (FBS) was from Armour Pharmaceutical Company, Kankakee, Illinois. Pooled human serum, which was heat-inactivated at 56°C for 30 minutes to remove immunoreactive LPL-like material, was obtained as described previously.20

Subject Selection

Healthy subjects (17 men, 28 ± 4 years old, mean ± SD, and 17 women, 32 ± 8 years old) were recruited as controls. These subjects had concentrations of plasma apo B, triglyceride, and total, LDL, and HDL cholesterol between the 10th and 90th percentiles of the Lipid Research Clinic's Prevalence Study values.21 They met the following criteria: 1) a history of good health, 2) abstinence from drugs known to affect serum lipids, 3) an age below 60 years, 4) a body weight that was stable and below 120% of ideal body weight, 5) absence of excessive regular consumption of alcohol, and 6) no history of a recent acute illness.

Eight LPL-deficient patients referred to our Lipid Clinic at the University of Washington were studied, along with 28 available family members (Figure 1, Tables 1 and 2). Consanguinity was known to be present only in Family 2106. Patients with classical LPL deficiency had: 1) fasting hypertriglyceridemia with chylomicronemia, 2) an apparent postheparin LPL activity more than three standard deviations below the mean for normal subjects, and 3) lack of secondary causes of hypertriglyceridemia. Apo C-II deficiency and a plasma inhibitor to LPL were ruled out as the cause of chylomicronemia by demonstrating the persistent lack of LPL activity after dilution of the patient's plasma with normal plasma. In all subjects, informed consent for these studies was obtained, and procedures were approved by the Human Subjects Review Committee at the University of Washington.

Measurement of Plasma Lipoprotein Lipase Activity

All patients fasted overnight for at least 12 hours before study. An indwelling catheter was placed in an arm vein, and 10 to 20 ml of blood was collected in disodium EDTA tubes (for lipoprotein analysis) and 7 to 14 ml, in lithium heparin tubes (for lipolytic activity and mass assays). A heparin bolus of 80 units/kg was injected, and 10 minutes later, 7 to 14 ml of blood was collected in lithium heparin tubes for the determination of LPL activity and mass. Samples were cooled on ice, and the plasma was separated after centrifugation (3000 g, 10 minutes at 4°C). The plasma samples were then stored at −70°C before assay.

Total postheparin plasma lipolytic activity was measured as previously reported.20 Aliquots of the enzyme
source were incubated with the substrate, tri-1,4-C-glutamate, for 60 minutes at 37°C, and the liberated free fatty acids were extracted and counted. Activity is expressed as nanomoles of fatty acids released per minute per milliliter of plasma. To determine hepatic triglyceride lipase (HTGL) and LPL activity, LPL was selectively blocked by the monoclonal antibody, 5D2, obtained as described below. This monoclonal antibody binds LPL and inhibits human, bovine, and rabbit LPL activity. The 5D2 monoclonal antibody completely blocked activity of human adipose tissue LPL. LPL activity was calculated as the activity inhibited by this antibody when added to plasma. On each assay occasion, a bovine milk lipase standard and a human postheparin plasma standard were included to correct for interassay variation of assay substrate.

### Preparation of the 5D2 Antibody

Bovine milk LPL was purified and yielded one band on sodium dodecyl sulfate polyacrylamide electrophoresis.22 Purified LPL (250 μg/ml) was emulsified with an equal volume of Freund’s complete adjuvant, and aliquots (25 μg of LPL) were administered subcutaneously to specific pathogen-free female Balb/CJ mice (Jackson Laboratories, Bar Harbor, ME), with intraperitoneal booster doses at 5 and 8 weeks plus intravenously (50 μg in 0.1 ml of sterile saline) at 11 to 15 weeks. Four days after the last antigen injection, splenocytes were harvested and were fused with an equal number (5 x 10⁴) of P3X63 Ag 8.653 mouse myeloma cells (American Type Culture Collection, Rockville, MD) by using PEG 4000. The fused cells were maintained on feeder macrophages obtained by peritoneal lavage of mice in selection medium (DMEM with 2 mM glutamine, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol, and 10% FBS) containing hypoxanthine, aminopterin, and thymidine.23 The clones that produced antibodies reacting with LPL were identified by screening the culture media with an ELISA.24 Briefly, bovine LPL (1 μg/ml) in phosphate-buffered saline (PBS) was adsorbed at 37°C for 1 hour on microtiter plates (100 μl/well). The wells were rinsed three times with PBST (PBS containing 15% glycerol (vol/vol), 1% Tween 20 (vol/vol), and 1 mg/ml sodium heparin), then incubated with tissue culture media (3- to 100-fold dilution) in PBST with horseradish peroxidase-labeled goat antimouse IgG (2000-fold dilution). Peroxidase activity was assayed as described by Engvall.25 One antibody (5D2) identified as the most potent inhibitor of LPL activity was grown in ascites tumors from mice primed with Pristane.26 The 5D2 antibody was then purified from ascites fluid by sequential caprylic acid and ammonium sulfate precipitation with 5.7 to 13.8 mg of IgG recovered per milliliter of ascites fluid. An antibody dose-response inhibition curve for LPL by the 5D2 antibody demonstrated that the 5D2 antibody completely inhibited catalytic activity at 10⁻³ dilution of ascites fluid. Despite the homology between LPL and hepatic lipase, the 5D2 antibody was specific for LPL and did not inhibit a partially purified hepatic lipase preparation obtained after heparin agarose chromatography. The immunoglobulin subclass of 5D2 was identified as IgG by ELISA with subclass-specific goat antimouse immunoglobulin sera and horseradish peroxidase-labeled rabbit anti-goat IgG antibodies.

### Enzyme-linked Immunoassay for Lipoprotein Lipase Mass

The 5D2 antibody (0.4 μg/ml in 200 μl of PBS) was incubated in microtiter wells at 37°C for 4 hours. Plates were then rinsed three times with PBST and stored at 4°C for up to 1 week. Purified bovine LPL standards were stored at -70°C and were mixed with pooled human plasma at 4°C before assay. Standards (0 to 100 ng) were run in quadruplicate, were incubated in microtiter wells (200 μl/well pretreated with antibody) at 4°C for 20 hours, and then were rinsed four times with PBST at room temperature. 5D2 antibody was conjugated to horseradish peroxidase.24 It was diluted 1:10 000 with 0.25% Tween 20 (vol/vol) in PBS, and was added (200 μl) to the plates and then incubated at room temperature for 3 hours. The

---

**Table 1. Clinical Data for Lipoprotein Lipase-Deficient Patients**

| Family | Pedigree Position | Age (Yrs) | Sex | TG (mg/dl) | TC (mg/dl) | LDL-C (mg/dl) | HDL-C (mg/dl) | VLDL-C (mg/dl) | Apo B (mg/dl) | Act (nmol/min/ml) | Mass (ng/ml) |
|--------|------------------|-----------|-----|------------|------------|---------------|---------------|----------------|---------------|-----------------|--------------|
| 2105   | II-2             | 21        | F   | 1995       | 361        | 24            | 14            | 323            | 98            | 0               | 35           |
| 2106   | II-2             | 40        | M   | 2040       | 287        | 19            | 12            | 256            | 96            | 0               | 38           |
| 2107   | III-1            | 13        | F   | 3680       | 337        | -             | -             | -              | -             | 5              | 59           |
| 2107   | III-2            | 7         | F   | 2400       | 222        | -             | -             | -              | -             | 3              | 25           |
| 2108   | II-1             | <1        | F   | >1575      | 474        | -             | -             | -              | -             | 4              | 50           |
| 2109   | III-1            | 5         | F   | 2700       | 258        | -             | -             | -              | -             | 18             | 2            |
| 2110   | III-2            | 1         | M   | 776        | 185        | 54            | 9             | 113            | 94            | 24             | 103          |
| 2110   | III-3            | 7         | M   | 3408       | 348        | 32            | 13            | 303            | 93            | 16             | 59           |
| Controls* |               |           |     |            |            |               |               |                |               | 227±50         | 212±64       |
|        |                  |           |     |            |            |               |               |                |               | 212±60         | 179±50       |
| Totals |                  |           |     |            |            |               |               |                |               | 220±59         | 196±59       |

*There were 17 male and 17 female controls.

TG = total triglyceride, TC = total cholesterol, LDL-C = low density lipoprotein cholesterol, HDL-C = high density lipoprotein cholesterol, VLDL-C = very low density lipoprotein cholesterol, Apo B = apoB/apoB protein, B, LPL Act = lipoprotein lipase activity, LPL Mass = lipoprotein lipase mass.
Table 2. Clinical Data of Relatives

| Pedigree | Age (yrs) | Sex | TG* (mg/dl) | TC* (mg/dl) | LDL-C | HDL-C | Apo B | Pheno- | Act | Mass |
|----------|-----------|-----|-------------|-------------|-------|-------|-------|--------|-----|------|
| Family   |           |     |             |             |       |       |       | type   |     |      |
| Obligate heterozygotes |
| 2105     | I-1       | 42  | M           | 69          | 167   | 100   | 53    | 104    | NL  | 72   |
| 2105     | I-2       | 40  | F           | 52          | 227   | 161   | 56    | 133    | NL  | 133  |
| 2106     | I-1       | 70  | M           | 64          | 159   | 105   | 37    | 98     | NL,IV| 77   |
| 2106     | II-2      | 83  | F           | 149         | 215   | 126   | 57    | 126    | NL  | 159  |
| 2106     | III-1     | 11  | M           | 249         | 209   | 126   | 33    | 109    | II-B| 125  |
| 2106     | III-2     | 9   | M           | 53          | 184   | 130   | 43    | 103    | NL,II-B| 132  |
| 2107     | II-2      | 32  | F†          | 182         | 236   | —     | —     | —      | II-B,IV| 119  |
| 2107     | II-3      | 37  | M†          | 210         | 345   | —     | —     | 221    | II-A,II-B| 124  |
| 2106     | I-1       | 32  | M†          | 372         | 174   | 73    | 27    | 73     | IV  | 36   |
| 2108     | I-2       | 32  | F†          | 108         | 206   | 137   | 47    | 91     | NL  | 62   |
| 2109     | I-1       | 30  | M†          | 77          | 122   | 78    | 29    | 58     | NL  | 122  |
| 2109     | I-2       | 30  | F†          | 121         | 210   | 144   | 42    | 124    | NL  | 102  |
| 2110     | II-1      | 35  | M           | 114         | 224   | 153   | 46    | 132    | NL  | 101  |
| 2110     | II-2      | 35  | F           | 231         | 248   | 167   | 41    | 136    | NL,II-B| 101  |
| Potential heterozygotes |
| 2105     | II-1      | 22  | M           | 46          | 173   | 108   | 55    | 89     | NL  | 270  |
| 2105     | II-3      | 7   | F           | 33          | 188   | 109   | 77    | 88     | NL  | 244  |
| 2106     | III-4     | 11  | M           | 43          | 158   | 87    | 62    | 76     | NL  | 159  |
| 2107     | I-1       | 70  | F†          | 133         | 241   | —     | —     | —      | NL  | 234  |
| 2107     | III-3     | 5   | F†          | 68          | 141   | —     | —     | —      | NL  | 213  |
| 2110     | II-1      | 62  | M           | 286         | 223   | 115   | 29    | 120    | NL  | 207  |
| 2110     | I-2       | 62  | F           | 150         | 280   | 197   | 66    | 156    | NL  | 303  |
| 2110     | I-4       | 87  | F           | 222         | 231   | 151   | 47    | 142    | NL  | 223  |
| 2106     | II-3      | 40  | M           | 118         | 181   | 124   | 33    | 130    | NL,IV| 72   |
| 2106     | II-4      | 30  | F           | 84          | 164   | 105   | 42    | 88     | NL  | 123  |
| 2106     | III-3     | 12  | F           | 90          | 151   | 81    | 52    | 61     | NL  | 46   |
| 2107     | II-1      | 29  | M†          | 242         | 231   | —     | —     | 135    | NL,II-B| 122  |
| 2110     | I-3       | 67  | M           | 110         | 221   | 138   | 57    | 114    | NL  | 106  |
| 2110     | III-1     | 12  | M           | 151         | 176   | 109   | 41    | 97     | NL,IV| 198  |
| Controls‡ |
| F         |           |     |             |             |       |       |       |        |     | 227±58|
| M         |           |     |             |             |       |       |       |        |     | 212±64|
| Totals    |           |     |             |             |       |       |       |        |     | 220±59|

LPL-DEFICIENT HETEROZYGOTE STATE  Babirak et al.  329
plates were then rinsed five times with PBST, and peroxidase activity was measured by absorbance at 492 nm. Standards of bovine or human LPL were linear to 100 ng/ml with a correlation coefficient typically greater than 0.97. A close correspondance was found between regression lines of bovine and human LPL, indicating that the ELISA detects enzyme from both sources with similar sensitivity. Heat inactivation of human enzyme demonstrated that enzyme mass was lost in parallel with enzyme activity.

LPL mass in patient samples was determined by using the ELISA described above and was calculated from the standard curve by using purified bovine LPL. LPL mass was measured in preheparin and postheparin plasma. The incremental LPL mass released into the plasma after heparin administration was calculated by subtracting preheparin from postheparin plasma mass. Samples were measured in duplicate, and the interassay variation was 7.9%, within an intra-assay variation of 2.6%. A human postheparin plasma lipase standard was included to correct for interassay variation.

Other Procedures

Total cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol, and total triglycerides were measured according to modified procedures of the Lipid Research Clinic. Apo B was measured by radioimmunoassay. Hyperlipidemia was diagnosed if a subject's age-adjusted plasma level was above the 95th percentile for total cholesterol (type IIA) or total triglyceride (type IV), or if both total cholesterol and total triglyceride were above the 90th percentile (type IIIB). The control population for lipids was defined as the Lipid Research Clinic control population matched for age and sex. The control population for apo B was defined from a Seattle control population.

Statistical Methods

Data were analyzed by: 1) unpaired Student's t test, 2) regression analysis, 3) Fisher's exact test, and 4) χ² analysis. The results are expressed as means ± SD. The ellipse that describes the 95th percentile confidence limits of activity and mass for the controls was calculated from the mean and variance of the enzyme activity and the enzyme mass plus the covariance between them as described by Zelen and Severo.

Results

Lipoprotein Lipase Activity and Mass in Postheparin Plasma from Control Subjects

LPL activity was similar in the 17 normolipidemic men (212 ± 60 nmol/min/ml) and 17 women (227 ± 58) and the values were, therefore, combined (220 ± 59). Similarly, values for LPL mass in the men (179 ± 50 ng/ml) and women (212 ± 64) were combined (196 ± 59). The postheparin plasma activity correlated with the incremental enzyme mass in these 34 controls (Figure 2) (r = 0.83, p < 0.001), indicating that the specific activity of the postheparin plasma enzyme of these normolipidemic subjects was fairly uniform (1.15 ± 0.20 nmol/min/ng, coefficient of variation = 17%). This high correlation between activity and mass, which appears in postheparin plasma, adds strength to the concept that the ELISA measures releasable enzyme mass, since enzyme activity is determined by independent means.

Detection of Heterozygote State

Most LPL-deficient patients have absent or low LPL activity and incremental LPL mass (Figure 3). However, some patients had low activity and detectable enzyme mass, a finding that is consistent with a defective enzyme protein. Since LPL deficiency is an autosomal recessive disorder, obligate heterozygotes are defined as the parents or the offspring of an LPL-deficient patient. The obligate heterozygotes from two families had reduced LPL and fell below the 95th percentile confidence limits for LPL activity and mass compared to the controls, except for one

![Figure 2. Postheparin plasma lipoprotein lipase activity (nmol/min/ml) and incremental mass (ng/ml) in 34 normolipidemic adults (M=males, F=females). The ellipsoid dashed line includes the 95% confidence limits for activity and mass, which was calculated from the mean and variance of both activity and mass plus the covariance between them.](image)

![Figure 3. Postheparin plasma lipoprotein lipase (LPL) activity (nmol/min/ml) and incremental mass (ng/ml) in LPL-deficient patients (M, n=8) compared to controls (O, n=34). The ellipsoid dashed line includes the 95% confidence limits for LPL activity and mass as described in Figure 1.](image)
LPL-DEFICIENT HETEROZYGOATE STATE

mid hyperlipidemia was present in ten of the relatives of LPL-deficient patients. An example of this mild hyperlipidemia is depicted in Family 2106. The LPL-deficient patient (II-2) has a son (III-2), a brother (II-3), and a father (I-1) with variable hyperlipidemia, as well as a son (III-1) with elevated serum cholesterol and triglyceride. Three of six affected first-degree relatives were normolipidemic on one occasion and hypertriglyceridemic (I-1, II-3) or hypertriglyceridemic and hypercholesterolemic (III-2) on another occasion. Since the proband’s parents were cousins, the mother and father most likely contributed the same mutant gene; therefore, different gene defects cannot account for this variability. When measured, the LDL cholesterol was above the 90th percentile in the hypercholesterolemic heterozygotes (n = 3), indicating that the increase in total cholesterol could be accounted for in the LDL fraction. The hyperlipidemia segregates with the heterozygote state in these families. Ten of 20 heterozygotes were hyperlipidemic, while all relatives with normal LPL (n = 8) were normolipidemic (p < 0.03).

LPL-deficient probands have markedly reduced HDL cholesterol (Table 1). The heterozygotes for LPL deficiency were also characterized in this study by reduced HDL cholesterol (Table 2). In 10 of 17 heterozygotes, the HDL cholesterol was below the 25th percentile, while only three of 17 heterozygotes were above the 50th percentile. Quartile x² analysis showed that HDL cholesterol was reduced in the LPL-deficient heterozygotes compared to the Lipid Research Clinic’s control population (p < 0.01). Plasma apo B levels were above the 90th percentile in six of the 16 adult heterozygotes, while one of the relatives with normal LPL had an apo B above the 90th percentile.

Discussion

Since LPL deficiency is a rare clinical disorder having a frequency approximately equal to the homozygote state of familial hypercholesterolemia (1 in 1 million), the heterozygote state of each disorder may also have similar frequencies (approximately 1 in 500). It has been difficult to characterize the heterozygote state for LPL deficiency since both the nonspecific measurement of postheparin lipolytic activity and the specific measurement of LPL activity have been unreliable in identifying heterozygotes.7–13 It has been reported4 that adipose tissue LPL activity from subcutaneous fat biopsies is depressed to about 50% of normal in the parents and healthy sibs of one LPL-deficient subject in a small nuclear family. However, measurement of adipose tissue LPL activity could not identify heterozygotes in another family with an extended pedigree.9 These observations would appear to contradict the expectation that enzyme levels should be reduced to about 50% of normal in heterozygotes for an autosomal recessive disorder such as LPL deficiency. However, when both LPL activity and mass are used to compare obligate heterozygotes for LPL deficiency to normal controls, it becomes apparent that the heterozygotes have reduced LPL and fall below the 95th percentile confidence limits of the control subjects. Using this technique, we can now identify heterozygote individuals in families with patients with LPL deficiency.

Figure 4. Postheparin plasma lipoprotein lipase (LPL) activity (nmol/min/ml) and incremental mass (ng/ml) in obligate heterozygotes (△, n = 14) in the families of eight LPL-deficient patients compared to the 95% confidence limits for LPL activity and mass (n = 34) indicated by the ellipsoid dashed line.

Figure 5. Postheparin plasma lipoprotein lipase (LPL) activity (nmol/min/ml) and incremental mass (ng/ml) in potential heterozygotes (△, ●, n = 14). The area enclosed by the dashed line includes the 95% confidence limits for activity and mass. The potential heterozygotes were separated into groups with normal LPL (●, n = 8) and detected heterozygotes (△, n = 6). See text for details.

obligate heterozygote (Family 2105:II-2), whose LPL fell between the 90th and 95th percentile confidence limits (Figure 4). When comparing only LPL activity, there was some overlap between the heterozygotes and normal controls, which may explain why previous attempts at detection of the heterozygote state were unsuccessful. However, by using both LPL activity and mass, the heterozygotes appeared to have abnormal LPL because they fell outside these 95th percentile confidence limits.

From these six families, 14 other family members who were potential heterozygotes (i.e., they had a 50% chance of inheriting one abnormal gene for LPL deficiency) were sampled. With the combined measurement of LPL activity and LPL mass, eight of the 14 potential heterozygotes had normal LPL, while six were classified as heterozygotes because they had reduced LPL and fell below the 95th percentile confidence limits of normal (Figure 5). In Family 2110, one would expect that a paternal grandparent of the proband should be a heterozygote. Since both grandparent's have normal LPL, either we are unable to detect the heterozygote, or the first affected individual (II-1) had abnormal LPL due to a new mutation in this family.

Characterization of the Heterozygote State

Plasma lipids were analyzed in the relatives from six families (Figure 1 and Table 2). In four of the six families,
addition, this technique has allowed us to initially characterize the heterozygote state.

Although hyperlipidemia is not observed in all families of LPL-deficient probands,\(^6\) this study demonstrates that the mild variable hyperlipidemia observed in some families of LPL-deficient probands segregates with the heterozygote state for LPL deficiency. Not all of the heterozygotes had hyperlipidemia, and the heterozygotes who had their lipids measured on more than one occasion demonstrated that their lipid profile could vary from one abnormal phenotype to another or could be normal. This pattern of hyperlipidemia seen in successive generations, which varies within and between individuals, has been reported by several investigators.\(^9\) This study indicates that pattern seen in the families with FCHL. Some adult heterozygotes for LPL deficiency had elevated apo B levels, which also makes these heterozygotes appear similar to patients with FCHL. Wilson et al.\(^9\) proposed a second genetic defect to explain the hyperlipidemia in the family of one LPL-deficient patient; however, LPL-deficient heterozygotes could not be reliably identified in this study. The present study suggests that the lipoprotein abnormalities and the heterozygote state for LPL deficiency are due to a common gene defect in these families with an LPL-deficient proband.

One interesting feature observed in this study is the expression of hyperlipidemia in some children who are heterozygotes for LPL deficiency. Other studies have also documented hyperlipidemia in children from families with an LPL-deficient proband.\(^7\) It has been reported that a decrease in LPL is associated with a decrease in VLDL fractional catabolism,\(^3\) which would explain the hypertriglyceridemia we saw. The decrease in HDL cholesterol would be explained by the reduced hydrolysis of VLDDL triglyceride, resulting in a decreased contribution of VLDL surface components to HDL.\(^3\) The combined presence of hypertriglyceridemia and hypercholesterolemia, which has also been reported in heterozygotes for LPL deficiency, could be related to a defective clearance of serum triglyceride leading to an increase in precursor lipoproteins for LDL synthesis.

The occurrence of hypercholesterolemia due to elevated LDL levels alone is more difficult to explain but has been a consistent observation in these families. There are several possible mechanisms to account for this observation. LPL appears to facilitate the uptake of free cholesterol during chylomicron hydrolysis in perfused mammary gland and adipose tissue.\(^3\) The transfer of cholesteryl ester from plasma lipoproteins to cells also appears more active in those cells that produce LPL.\(^2\) In perfused rat heart, cultured rat heart cells, and cultured preadipocytes, chylomicron cholesteryl ester uptake required LPL and was markedly reduced after LPL was displaced from the capillary endothelium or the cell surface by heparin. This uptake of cholesteryl ester was distinct from the LDL receptor pathway and did not require that triglyceride hydrolysis be functional. Several additional studies suggest that the increased transmembrane transport of cholesteryl ester in cells with LPL is somehow catalyzed by the enzyme, possibly by providing an extensive surface area for the removal and metabolism of phospholipid and cholesteryl ester.\(^6\)

The relationship of FCHL to the heterozygote state for LPL deficiency remains to be elucidated. Previous studies have demonstrated that LPL activity appears to be normal in patients with FCHL.\(^4\) Goldberg et al.\(^4\) studied five patients with FCHL who had normal LPL activity in adipose tissue during both the fasting and the postprandial state. Beil et al.\(^3\) studied 11 patients with FCHL who demonstrated normal postheparin LPL activity as a group, but three of these patients had reduced postheparin LPL activity as compared to normal controls. A recent study\(^1\) of six kindreds with FCHL demonstrated that LPL activity was no different between normotriglyceridemic and hypertriglyceridemic relatives, as well as normal controls. The proportion of patients with FCHL who are actually heterozygous for LPL deficiency remains to be determined. Previous studies have not distinguished between patients with FCHL who are and those who are not heterozygotes for LPL deficiency for several reasons: 1) the heterozygote state cannot be identified clinically, 2) biochemical markers for the heterozygote state were previously unreliable, and 3) FCHL is a relatively common disorder (1% to 2% of the population), while the heterozygote state is much less common (1:500), thus, any investigation has a selection bias against the heterozygote state. Now that there is a method for the detection of heterozygotes for LPL deficiency, it may be possible to identify what proportion of FCHL patients actually are heterozygotes for LPL deficiency.

In summary, a method that can reliably detect the heterozygote state for LPL deficiency is described. The heterozygotes had reduced LPL activity and mass, less than the 95th percent confidence limits of normal controls. Some of the heterozygotes had a mild variable hyperlipidemia, reduced HDL cholesterol, and may or may not have had elevated apo B levels, which make these patients clinically similar or indistinguishable from patients with FCHL. This study identified one genetic disorder, the heterozygote state for LPL deficiency, as a subset of FCHL. The prevalence of heterozygotes for LPL deficiency among patients with FCHL remains to be determined.

Acknowledgments

The authors are grateful for the excellent technical assistance of Martha Kimura, Steve Haabimoto, and the nurses from the Clinical Research Center at the University of Washington. The monoclonal antibody was developed by Mark Scheibel. We thank...
References

1. Brunzell JD, Iversus P-H, Schiebel MS, Fullerton WY. Primary lipoprotein lipase deficiency. In: Angel A, Frohlich J, eds. Lipodystrophy: syndromes and disorders. New York: Plenum Press, 1986:227-239
2. Niskilla EA. Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolism. In: Sturany JB, Wynaagard JB, Fredrickson DS, Goldwaner JL, Brown MS, eds. Disorders of lipoprotein and lipid metabolism. New York: McGraw-Hill, 1983:622-642
3. Friedrickson DS, Goldstein JL, Brown MS. The familial hyperlipoproteinemias. In: Sturany JB, Wynaagard JB, Fredrickson D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1978:604-655
4. Brunzell JD, Chait A, Niskilla EA, Ehhholm JK, Steiner G. Heterogeneity of primary lipoprotein lipase deficiency. Metababolism 1980;29:624-629
5. Harland WR Jr, Wisenstet PS, Wassermann AJ. Tissue lipoprotein lipase in normal individuals and in individuals with exogenous hypertriglyceridemia and the relationship of this enzyme to assimilation of fat. J Clin Invest 1967;46:239-247
6. Gordon JR, Harel RS Jr. Idiopathic hyperlipemia. Metabolic and familial aspects. J Clin Invest 1963:32:1777-1790
7. Gagne C, Brun D, Moodafar S, Lupid W-P. Hyperchylomicronemia familia: Étude de l'activité lipolipidique dans une famille. Un Med Can 1978;106:333-338
8. Fallin R, Boggio G, Poli A, et al. Familial lipoprotein lipase and apoprotein C-II deficiency. Lipoprotein and apoprotein analysis, adipose tissues and hepatic lipoprotein levels in seven patients and their first degree relatives. Atherosclerosis 1983:49:55-68
9. Wilson DE, Edwards CG, Chan IF. Phenotypic heterogeneity in the extended pedigrees of a proband with lipoprotein lipase deficiency. Metabolism 1983:32:1107-1114
10. Kondo Y, Kurobame I, Omura K, et al. Postheparin plasma lipoprotein lipase activity in heterozygotes of familial lipoprotein lipase deficiency. Tsubok J Exp Med 1985:145:1-6
11. Friedrickson DS, Levy R. Familial hyperlipoproteinemia. In: Sturany JB, Wynaagard JB, Fredrickson DS, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1972:545-511
12. Potter JM, Macdonald WB. Primary type I hyperlipoproteinemia: A metakinet and family study. Aust NZ J Med 1979; 9:888-963
13. Lambers S, Caspari AF, Melenow K, Hennenga G. Hulstam HAM. Thyrdoxine binding globulin deficiency in a family with type I hyperlipoproteinemia. Clin Endocrinol 1977:69:179-200
14. Burton BK, Nadler HL. Primary type I hyperlipoproteinemia with normal lipoprotein lipase activity. J Pediatr 1977:90:777-779
15. Bergersen HM, Bonnici F. Familial hypercholesterolemia in four families. S Afr Med J 1977:51:629-632
16. Schreiber PH, Arons DL, Seuduck CD, Arky RA. Abnormal lipoprotein lipase in family exogenous hypertriglyceridemia. J Clin Invest 1978:62:2075-2086
17. Ford S, Schiebel M, Glueck CJ, Bozlan RC. Familial hyperchylomicronemia. Enzymatic and physiologic studies. Am J Med 1971:50:536-541
18. Nevin NC, Fleck J. Hyperlipidemic xanthomatosis. II. Mode of inheritance in SS families with essential hyperlipidemia and xanthomas. J Med Genet 1968:5:20-28
19. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203-207
20. Iversus P-H, Brunzell J. Human adipose tissue lipoprotein lipase. Changes with feeding and relationship to postheparin plasma enzyme. Am J Physiol 1985:249:E107-E114
21. Lipid Research Clinics Program. Population Studies data book. vol 1: The prevalence study. NIH publication no. 80-1527. Washington, DC: U.S. Government Printing Office
22. Iversus P-H, Ostlund-Lundqvist AM. Lipoprotein lipase from bovine milk: isolation procedure, chemical characterization and molecular weight analysis. J Biol Chem 1978;253:7781-7785
23. Fazekas de St. Groth S, Scheldkagger D. Production of monoclonal antibodies: Strategy and tactics. J Immunol Methods 1980:351-364
24. Voller A, Bidwell D. Enzyme-linked immunosorbtent assay. In: Ross NR, Friedman M, Fahey JL, eds. Manual of clinical immunology, 34th ed. Washington, DC: American Society for Microbiology, 1984:99-109
25. Engvall E. Enzyme immunoassus ELISA and EMIT. In: Van Yanukas H, Luschei JE, eds. Methods in enymology, vol 70. New York: Academic Press, 1980:419-439
26. Steinbuch M, Audran R. The isolation for IgG from mammarion sera with the aid of cetylic acid. Arch Biochem Biophys 1965;105:3-84
27. Lipid Research Clinics Program. Manual of laboratory operations, vol 1: Lipid and lipoprotein analysis. (DHEW publication no. (NIH) 75-628). Bethesda, MD: National Institutes of Health, 1974:51-58
28. Albers JJ, Cabana VG, Hazzard WR. Immunassus of human plasma apolipoprotein B. Metabolism 1975:24:1339-1351
29. Albers JJ, Brunzell JD, Knopp RH. Apoprotein measurements and their clinical application. In: Rifkin B, Lippel K, eds. Clinics in laboratory medicine, vol 8, Cholesterol screening, diagnosis, and therapy. WB Saunders, 1983 (in press)
30. Zelen M, Severo NC. Probability functions. In: Abramowitz M, Stegun IA, eds. Handbook of mathematical functions. New York: Dover, 1962:955-955
31. Snidman A, Tang B, Genest J, Claintone K, Wacholder S, Kwiterovich P. Familial aggregation and early expression of hyperapoEapolipoproteinemia. Am J Cardiol 1985:55:291-295
32. Goldstein JD, Schorr HT, Hazzard WR, Bierman EL. Hyperlipidemia in coronary disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new disorder, combined hyperlipidemia. J Clin Invest 1973:52:1544-1560
33. Megilli P, Rao SN, Miller NC, et al. Relationships between the metabolism of high density and very low density lipoproteins in man: studies of apoapoprotein kinesins and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 1982; 12:113-120
34. Zilber O, Mendelzos CR, Blanchette-Mackie EJ, Scow RO. Lipoprotein lipase and uptake of chylomycin triacylglycerol and cholesteryl esters into perfused rat mammary tissue. Biochim Biophys Acta 1976:431:526-537
35. Scow RO, Blanchette-Mackie EJ, Smith LG. Role of capillary endothelium in the clearance of chylomicrons. A model for lipid transport from blood by lateral diffusion in cell membranes. Circ Res 1976:39:149-162
36. Fielding CJ. Metabolism of cholesterol rich chylomicrons. J Clin Invest 1978;62:141-151
37. Chajek-Shaul T, Friedman G, Halperin G, Stein O, Stein Y. Uptake of chylomycin "H" cholesterylinic ester by mesenchymal rat cell cultures. Biochim Biophys Acta 1985:866:147-155
38. Friedman G, Chajek-Shaul T, Stein O, Ovchersona T, Stein Y. Role of lipoprotein lipase in the assimilation of cholesterylinic ete by cultured cell incubated with labelled chylomicrona. Biochim Biophys Acta 1980:156:156-165
39. Chajek-Shaul T, Friedman G, Stein O, Ovchersona T, Stein Y. Binding of lipoprotein lipase to the cell surface is essential for the transmembrana transport of chylomycin cholesterol esters. Biochim Biophys Acta 1982:712:200-210
40. Stein O, Goldin G, Kalander G, Ovchersona T, Stein Y. Lipoprotein lipase mediated uptake of non-degradable ether analogues of phosphatidycholine and cholesterol
ester by cultured cells. Biochim Biophys Acta 1984; 795:47-59
41. Taskinen MR. Lipoprotein lipase in hypertriglyceridemias. In: Borensztajn J, ed. Lipoprotein lipase. Chicago: Evener, 1987:201-228

42. Goldberg AP, Chait A, Brunzell JD. Postprandial adipose tissue lipoprotein lipase activity in primary hypertriglyceridemia. Metabolism 1980;29:223-229
43. Bell U, Grundy SM, Crouse JR, Zech L. Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis 1982;2:44-57

Index Terms: lipoprotein lipase • familial combined hyperlipidemia • triglyceride • cholesterol • apolipoprotein B